MetaVia shares preclinical data showing DA-1726 matches retatrutide weight loss with stronger glucose and lipid effects

MetaVia Inc. presented preclinical results from a head‑to‑head study of its GLP‑1/glucagon dual‑agonist DA‑1726 versus retatrutide at ObesityWeek 2026. In diet‑induced obese mice, DA‑1726 raised hepatic FGF21 expression, lowered plasma glucose by up to 43 % and cut total cholesterol by about 71 %, while achieving weight loss comparable to retatrutide with less reduction in food intake. The company said it will begin a Phase 2 trial in metabolic and alcohol‑associated liver disease in the second half of 2027.

The data suggest DA‑1726 may offer a differentiated metabolic profile that could attract investors if the Phase 2 trial confirms efficacy, potentially expanding MetaVia’s pipeline in liver‑related cardiometabolic indications.

  • 1The preclinical study was presented on November 14, 2026 at ObesityWeek 2026 in Washington, D.C.
  • 2DA‑1726 increased hepatic FGF21 gene expression and liver FGF21 protein levels (p<0.05 for gene, p<0.001 for protein).
  • 3Plasma glucose fell by 43.0 % at the low dose and 39.2 % at the high dose of DA‑1726, versus 21.5 % and 32.5 % for retatrutide.
  • 4Total cholesterol was reduced by 70.9 % and 69.3 % with DA‑1726, compared with 60.9 % and 69.0 % for retatrutide.
  • 5Body weight decreased by 34.2 % and 41.7 % with DA‑1726, versus 33.7 % and 43.6 % for retatrutide.
  • 6Food intake was reduced by 19.6 % and 31.2 % with DA‑1726, compared with 36.7 % and 41.4 % for retatrutide.

Sources